X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the merger, the company will focus on the clinical development of TRX100 (viroksavir), a CEN inhibitor. Currently, it is being evaluated in the Phase I clinical trial studies for the treatment of influenza.
Lead Product(s): Viroksavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TRX100
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Traws Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 02, 2024
Details:
ON 01910 (rigosertib) is a small molecule that inhibits multiple cell signaling pathways that drive cancer growth while having little effect on normal cells. In contrast to many kinase inhibitors.
Lead Product(s): Rigosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: ON 01910
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
ON123300 (narazaciclib) is a multi-kinase inhibitor targeting CDK 4, CDK 6, and other kinases important for cell proliferation and motility. It is being investigated in combination with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC).
Lead Product(s): Narazaciclib,Letrozole
Therapeutic Area: Oncology Product Name: ON 123300
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
The collaboration will leverage Pangea Biomed’s proprietary algorithmic platform, ENLIGHT, for identifying biomarkers of response to Onconova’s proprietary investigational ON-01910 (rigosertib) with the ability to potently inhibit PLK1 to treat a range of solid cancers.
Lead Product(s): Rigosertib,Nivolumab
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Pangea Biomed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2023
Details:
ON-01910 (rigosertib) is an investigational product candidate with a multi-faceted mechanism of action targeting proteins containing the RAS binding domain, allowing it to modulate the PI3K and PLK-1 pathways, as well as the tumor immune microenvironment.
Lead Product(s): Rigosertib
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
ON-01910 (rigosertib) is a small molecule that inhibits multiple cellular signaling pathways driving cancer cell growth. The studied doublet study has been generally well tolerated. Treatment-related adverse events (TRAE) have been mostly mild and manageable.
Lead Product(s): Rigosertib,Nivolumab
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
In vitro and cell-based assays suggest ON 123300 (narazaciclib)'s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitors.
Lead Product(s): Narazaciclib
Therapeutic Area: Oncology Product Name: ON 123300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Narazaciclib (ON 123300) is a multi-kinase inhibitor targeting CDK 4/6 and additional kinases involved in tumor genesis, which presents an innovative approach to treating advanced cancers resistant to commercial CDK 4/6 inhibitors.
Lead Product(s): Narazaciclib
Therapeutic Area: Oncology Product Name: ON123300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
ON 123300 (narazaciclib), a multi-kinase inhibitor targeting CDK 4/6, is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies for the treatment of HR+ HER2- metastatic breast cancer.
Lead Product(s): Narazaciclib
Therapeutic Area: Oncology Product Name: ON123300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
The trial continues to recruit patients as part of the expansion phase at the highest dose of oral rigosertib defined in the current protocol.
Lead Product(s): Rigosertib,Nivolumab
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
